The proposed definition of a partial virological response (PVR) to nucleos(t)ide analogue therapy in the 2009 European Association for the Study of the Liver (EASL) guidelines is based on limited evidence, especially in terms of the cutoff HBV DNA level and the time point at which to judge it. This study assessed optimal PVR criteria for predicting virological response (VR) at week 96 in treatment-naive patients with chronic hepatitis B (CHB) receiving entecavir (ETV).
Methods
A total of 175 patients (126 men, 49 women) who completed 96 weeks of first-line ETV therapy were prospectively recruited. For predicting VR at week 96, the area under the receiver operating characteristic curve (AUC) was used to find the optimal time point and the Youden index was used to calculate the optimal cutoff HBV DNA level.
Results
After 96 weeks of ETV therapy, 139 (79.4%) patients achieved VR. The AUC at week 48 was significantly better than that at week 24 for predicting VR at week 96 (P=0.023). The optimal cutoff HBV DNA level at week 48 was 35 IU/ml. Forty-one (23.4%) patients met this PVR criteria of ETV (HBV DNA level >35 IU/ml at week 48).
Conclusions
An HBV DNA level >35 IU/ml at week 48 is the optimal PVR criteria for predicting non-VR at week 96 in treatment-naive patients with CHB who are receiving ETV. This study supports the proposed EASL PVR for ETV based on scientific evidence.
References
1.
Hepatitis B vaccines: WHO position paper – recommendations. Vaccine2010; 28: 589–590.
2.
LeeW.M.Hepatitis B virus infection. N Engl J Med1997; 337: 1733–1745.
3.
ChenC.J., YangH.I., SuJ.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006; 295: 65–73.
4.
IloejeU.H., YangH.I., SuJ., JenC., YouS., ChenC.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology2006; 130: 678–686.
5.
KeeffeE.B., DieterichD.T., HanS.B.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol2008; 6: 1315–1341.
6.
LiawY.F., LeungN., KaoJ.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int2008; 2: 263–283.
7.
LokA.S., McMahonB.J.Chronic hepatitis B. Hepatology2007; 45: 507–539.
8.
AhnS.H., ChanH.L., ChenP.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int2010; 4: 386–395.
9.
European Association For The Study Of The Liver UH.EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol2009; 50: 227–242.
10.
LamperticoP.Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol2009; 50: 644–647.
11.
LaiC.L., GaneE., LiawY.Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med2007; 357: 2576–2588.
12.
SafadiR., XieQ., ChenY., YinY-K, WeisY., HwangS.A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at Week 24. J Hepatol2007; 46Suppl 1: S196.
13.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008; 359: 2442–2455.
14.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology2006; 131: 1743–1751.
15.
LaiC.L., ShouvalD., LokA.S.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med2006; 354: 1011–1020.
16.
ChangT.T., GishR.G., de ManR.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med2006; 354: 1001–1010.
17.
LeungN., PengC., HannH.Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology2009; 49: 72–79.
18.
TenneyD.J., PokornowskiK.A., RoseR.E.Entecavir maintains a high genetic barrier to HBV resistance through 6 years of naive patients. J Hepatol2009; 50Suppl 1: S10.
19.
GuoJ.J., LiQ., ShiX.Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res2009; 81: 180–183.
20.
SuzukiF., AkutaN., SuzukiY.Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol2007; 39: 149–152.
21.
ChoJ.H., YoonK., LeeK.Distribution of hepatitis B virus genotypes in Korea. Korean J Hepatol2009; 15: 140–147.
22.
BaeS.H., YoonS.K., JangJ.W.Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci2005; 20: 816–820.
23.
SongB.C., CuiX.J., KimH.Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology2005; 48: 133–137.
24.
ChoJ.H., ParkD., KimT.Genotypes of hepatitis B virus on Jeju island. Korean J Hepatol2004; 10: 42–50.
25.
LeeJ.M., KimH.J., ParkJ.Y.Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther2009; 14: 705–712.
26.
Martinot-PeignouxM., BoyerN., Cazals-HatemD.Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology2001; 34: 1000–1005.
27.
PersicoM., PersicoE., SuozzoR.Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology2000; 118: 760–764.
28.
Kim DoY., AhnS.H., LeeH.W.Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. Intervirology2008; 51: 293–298.
29.
LokA.S., ZoulimF., LocarniniS.Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology2007; 46: 254–265.
30.
AhnS.H., ParkY.N., ParkJ.Y.Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol2005; 42: 188–194.
31.
YuenM.F., FongD.Y., WongD.K., YuenJ.C., FungJ., LaiC.Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology2007; 46: 1695–1703.
32.
Kim DoY., KimS.U., AhnS.H.Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci2009; 54: 1758–1763.
33.
KimS.U., HanK., NamC.M.Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol2008; 23: 1722–1727.
34.
YoudenW.J.Index for rating diagnostic tests. Cancer1950; 3: 32–35.
35.
PerrilloR.P., MarcellinP.Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. Antivir Ther2010; 15: 13–22.
36.
YaoG.B., RenH., XuD.Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi2009; 17: 881–886.
37.
PanC., HuK.Excellent treatment response to tenofovir (TDF) monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir (ETV) monotherapy. Hepatology2008; 48Suppl 1: 725A.
